Form 10-Q · Quarterly report
Dexcom 10-Q, filed Oct 29, 2026
- Filed
- CIK
- 0001093557
- Accession no.
- 0001093557-26-000195
Summary
Dexcom reported third-quarter 2026 revenue of $1.34 billion, up 11% year over year, with operating income of $327.2 million and net income of $275.1 million, down 3%. The company also said Stelo received FDA clearance in June 2026 to expand its indication to children ages 2 and older who do not use insulin.
Key points
- Third-quarter 2026 revenue was $1.3445 billion, up 11% from $1.2093 billion a year earlier; gross profit was $864.4 million, operating income was $327.2 million, and net income was $275.1 million.
- Net income fell 3% year over year, while operating income rose 35% and gross profit rose 18%.
- Dexcom ended the third quarter of 2026 with $1.82 billion in cash, cash equivalents, and short-term marketable securities.
- Stelo, launched in August 2024 as the first over-the-counter glucose biosensor in the U.S., received FDA clearance in June 2026 for children ages 2 and older who do not use insulin.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2 - MANAGEMENT’S DISCUSSION Overview Who We Are We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.